| Search by tag or site | Login to my blog ? Start my own blog |
 |
BioHealth InvestorBioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network. |
Vaino's Biotech Corner Portfolio Update
Posted on 04/09/2007 18:54:21 | Link | Post Comment
by Andrew Vaino
Vaino's Biotech Corner
There have been some substantial moves in the BC tracking portfolio of late that I feel bear mentioning.
Clearly Biosante (BPA) has done well and is up 61%, though I am starting to wonder if it’s time to take profits here.
I still like Halozyme (HTI), up 240%. The stock has come down a bit the past few weeks but I still like it long term and don’t see any need to sell.
The Amylin (AMLN) 40 calls (YNN AH) are under water but, again, I like this company long term and am not worried about this.
Innovio (INO) is up a bit. This stock isn’t exciting me, but I think the company has potential and see no reason to sell.
Dendreon (DNDN) did exactly as I predicted last week and is up 29%—not bad for four days. The stock took off further Monday morning and is now trading above $20. I'm not sure how much of this is shorts covering and how much is hubris: either is working for me! To be safe I would put in a stop sell order at $20, this locks in a nice 42% profit.
Conjuchem (CJB.TO) took a big hit (down 25%) on results of a phase 1/2 clinical study of their diabetes treatment. Their PC-DAC form of Exendin-4 did produce relevant reductions in blood glucose levels, but at the highest dose 1 in 5 patients experienced nausea. This adverse event caused some analysts to suggest that the PC-DAC Exendin-4 would not be able to compete with Amylin’s long release form of Byetta.
For right now I’m not convinced this result is that bad. The diabetes market is huge and, thanks to excessive intake of carbohydrates since the mid 1980s, is growing fast. For a stock trading at 50 cents Conjuchem won’t have to take a huge slice of the diabetes pie to justify doubling or tripling in share price, and I see this as a buying opportunity.
Source: PeterNavarro.com
RELATED READING:
- Right on, Dendreon!
- Tiny Biosante Could Skyrocket with Estrogen Replacement Gel
- Conjuchem Biotechnologies: A Risky Canadian Diabetes Play
- Inovio Biomedical: Tumor Ablation Technology Tempting to Big Pharmas
- Halozyme Signs Deal with Roche, Continues to Impress
_____________________
Vaino's Biotech Corner
There have been some substantial moves in the BC tracking portfolio of late that I feel bear mentioning.
Clearly Biosante (BPA) has done well and is up 61%, though I am starting to wonder if it’s time to take profits here.
I still like Halozyme (HTI), up 240%. The stock has come down a bit the past few weeks but I still like it long term and don’t see any need to sell.
The Amylin (AMLN) 40 calls (YNN AH) are under water but, again, I like this company long term and am not worried about this.
Innovio (INO) is up a bit. This stock isn’t exciting me, but I think the company has potential and see no reason to sell.
Dendreon (DNDN) did exactly as I predicted last week and is up 29%—not bad for four days. The stock took off further Monday morning and is now trading above $20. I'm not sure how much of this is shorts covering and how much is hubris: either is working for me! To be safe I would put in a stop sell order at $20, this locks in a nice 42% profit.
Conjuchem (CJB.TO) took a big hit (down 25%) on results of a phase 1/2 clinical study of their diabetes treatment. Their PC-DAC form of Exendin-4 did produce relevant reductions in blood glucose levels, but at the highest dose 1 in 5 patients experienced nausea. This adverse event caused some analysts to suggest that the PC-DAC Exendin-4 would not be able to compete with Amylin’s long release form of Byetta.
For right now I’m not convinced this result is that bad. The diabetes market is huge and, thanks to excessive intake of carbohydrates since the mid 1980s, is growing fast. For a stock trading at 50 cents Conjuchem won’t have to take a huge slice of the diabetes pie to justify doubling or tripling in share price, and I see this as a buying opportunity.
Source: PeterNavarro.com
RELATED READING:
- Right on, Dendreon!
- Tiny Biosante Could Skyrocket with Estrogen Replacement Gel
- Conjuchem Biotechnologies: A Risky Canadian Diabetes Play
- Inovio Biomedical: Tumor Ablation Technology Tempting to Big Pharmas
- Halozyme Signs Deal with Roche, Continues to Impress
_____________________
- Mri To Lead Growth In Medical-imaging Market
- Malaria And Hiv - Eradication And Treatment
- Dragon’s New Production Process To Cut Costs
- Mrsa Update: Cepheid, Basilea And Nektar
- If Only Us Health Care Could Be More Like The Patriots (or Even The Red Sox) And Less Like The Yankees
- e-techblog
- Wishing Wealth
- Financial Skeptic
- Don't Mess With Taxes
- Millionaire Now! by Larry Nusbaum
- 360 Digest
Examples
Morpheus Trading - Thu Jul 17, 2008 01:15AM
NOTE: Please click on the charts below to enlarge them if th [read more]
NOTE: Please click on the charts below to enlarge them if th [read more]
Morpheus Trading - Mon Jul 21, 2008 08:33AM
NOTE: Please click on the charts below to enlarge them if [read more]
NOTE: Please click on the charts below to enlarge them if [read more]
The Swing of Things - Thu Jul 17, 2008 09:36AM
I used to make a pretty good living sharing hard won [read more]
I used to make a pretty good living sharing hard won [read more]
<< My Home | TheMoneyBlogs Home